Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-049870

HTG MOLECULAR DIAGNOSTICS, INC · HTGM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Aug 18, 2017
Accepted (ET)
Aug 22, 2017 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169987

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
COMMON STOCKF1Aug 18, 2017S55,100$2.098D1,225,085D
COMMON STOCKF2Aug 21, 2017S12,845$2.0223D1,212,240D
COMMON STOCKF3Aug 22, 2017S12,641$2.0103D1,199,599D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Novo Holdings A/S (formerly known as Novo A/S) is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard, Lars Rebien Sorensen and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.